Fludarabine – 25 mg

Brand:
Cayman
CAS:
21679-14-1
Storage:
-20
UN-No:
Non-Hazardous - /

Because of their antitumor activity via inhibition of DNA synthesis, purine nucleoside derivatives resistant to deamination have been developed for the treatment of various leukemias.{22555,21535} Fludarabine is an adenosine deaminase resistant analog of 9-β-D-arabinofuranosyladenine (ara-A) that disrupts ribonucleotide reductase and DNA polymerase in blood cells. It exhibits antiproliferative activity (IC50 = 1.54 μM in an RPMI-8226 myeloma cell line) and triggers apoptosis through increasing Bax and decreasing Bid, XIAP, and survivin expression.{22556,22553} Fludarabine is effective in a number of animal tumor systems including LI210 leukemia, CD8F mammary adenocarcinoma, P388 leukemia, and human LX-1 lung tumor xenograft and displays anticancer activity against human hematological malignancies in vivo.{22565,22552,22557}  

 

SKU: - Category:

Description

A nuclesoside analog that disrupts DNA synthesis in blood cells; effective in a number of animal tumor systems including LI210 leukemia, CD8F mammary adenocarcinoma, P388 leukemia, and human LX-1 lung tumor xenograft and displays anticancer activity against human hematological malignancies in vivo


Formal name: 9-β-D-arabinofuranosyl-2-fluoro-9H-purin-6-amine

Synonyms:  F-ara-A|NSC 118218

Molecular weight: 285.2

CAS: 21679-14-1

Purity: ≥98%

Formulation: A crystalline solid


Product Type|Biochemicals|Nucleotides/Nucleosides||Product Type|Biochemicals|Small Molecule Inhibitors|Nucleic Acid Turnover/Signaling||Research Area|Cancer|Cell Death|Apoptosis